A small-scale clinical study of the combined use of the AstraZeneca and Sputnik Light vaccines against COVID-19 has shown strong antibody growth in a majority of the study’s participants, the Russian Direct Investment Fund (RDIF) said on Monday.
The data was collected from 20 people who took part in a 100-person study in Azerbaijan that began in February.
They first received the AstraZeneca shot followed by the one-dose Russian-made Sputnik Light shot 29 days later, RDIF said.
“According to the results of the interim analysis, a fourfold or higher increase in neutralising antibodies to the spike protein (S-protein) of the SARS-CoV-2 was found in 85% of the volunteers on the 57th day of the study,” RDIF said.
Russia’s Sputnik V was the first vaccine against COVID-19 to be registered: